Week In Review: Eddingpharm Pays $169 Million For China Rights To Omega-3 Drug

February 28, 2015 -- Eddingpharm of China signed a deal worth up to $169 million for China rights to Vascepa®, a prescription omega-3 drug from Amarin of the US; Georgia State University out-licensed China rights for a potential leukemia-fighting drug to Cisen Pharma, headquartered in Shandong Province; Eisai of Japan announced plans to build a second new plant in the Suzhou Industrial Park to make oral solid dose products; TWi Pharma of Taiwan reacquired US distribution rights to two of its products from Teva, which TWi will now market itself; and MicuRx Pharma, a US-China company, was granted FDA approval to begin a US Phase II trial of its novel oral antibiotic, which MicuRx will pair with a similar China trial already underway.

Help employers find you! Check out all the jobs and post your resume.